PATENT CLAIM ANALYSIS

Application Number: 15954021
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["424", "009450"]

Abstract:
Disclosed herein are compositions and formulations containing a TATk-CDKL5 fusion protein. Also disclosed are methods of producing a TATk-CDKL5 fusion protein from vectors containing a TATk-CDKL5 cDNA and methods of transducing cells with the vectors containing a TATk-CDKL5 cDNA and the TATk-CDKL5 fusion protein

Claim (Index 50):
A method of treating a CDKL5 deficiency, Rett syndrome or a Rett syndrome variant, the method comprising administering a fusion protein to a subject in need thereof, wherein the fusion protein comprises:\n a CDKL5 polypeptide sequence, wherein the CDKL5 polypeptide sequence comprises SEQ ID NO: 16; and a TAT\u03ba polypeptide sequence, wherein the TAT\u03ba polypeptide sequence comprises SEQ ID NO: 4, wherein the TAT\u03ba polypeptide is operatively coupled to the CDKL5 polypeptide.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 91.0
- Lexical Diversity: 1.875
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14633757', '15075457', '14214161', '14518225', '15454662']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6887692992813743
- 35 USC 102 Novelty (BERT): 0.6462031022181104
- Combined Prediction Score: 0.6845126795750479
- Mean Citation Score: 425.008982
- Max Citation Score: 667.46564
- Similarity Product: 555.9785513336897

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test